Mireskandari Alidad, the President & COO of Niki BioSolutions, Inc., has reported significant stock transactions in a recent filing. The filing details the acquisition of 20,000 shares of common stock and options for an additional 80,000 shares. This move underscores Alidad's commitment to the company and its future direction.

Background

Niki BioSolutions, Inc. operates under the SIC classification of Measuring & Controlling Devices, NEC. The company, which trades under the ticker symbol NIKI, is based in Princeton, New Jersey. Alidad Mireskandari has been actively involved in the company, with recent filings indicating ongoing transactions that reflect a strategic focus on growth and development.

What the Filing Says

The filing, dated November 17, 2026, reveals that Alidad Mireskandari acquired 20,000 shares of common stock on July 22, 2026. Additionally, the filing reports the acquisition of 80,000 stock options, which are set to vest under specific conditions related to company performance.

Impact

This update may affect various stakeholders, including investors and employees of Niki BioSolutions. Alidad's increased ownership could signal confidence in the company's direction, potentially influencing investor sentiment and employee morale.

What's Next

The filing does not say what happens next.

Details of the Stock Options

The stock options acquired by Alidad Mireskandari come with specific vesting conditions that are tied to the performance and milestones of Niki BioSolutions. Of the 80,000 options, 40,000 will vest in eight equal quarterly installments, while the remaining options are contingent on various achievements. For instance, 5,000 options will vest upon the successful completion and publication of the clinical validation study of CogniMIR(R) to meet CLIA requirements. Additionally, 10,000 options will vest if the company enters into a biopharmaceutical services agreement that generates at least $250,000 in proceeds. Furthermore, 5,000 options will vest upon the company generating $1,000,000 in revenue, and another 10,000 options will vest following capital raises totaling $5,000,000. Lastly, 10,000 options are contingent on a 100% increase in the company's stock price after the merger that took place in July 2026.

Ownership Following Transactions

After the reported transactions, Mireskandari directly owns 20,000 shares of common stock and has a total of 80,000 stock options. The filing indicates that the stock options have an exercise price of $8.83 and will expire on July 22, 2036. The acquisition of these shares and options reflects Mireskandari's significant stake in the company's future performance.

Company Background and Recent Developments

Niki BioSolutions, Inc. is classified under the SIC code for Measuring & Controlling Devices, NEC, and is incorporated in New Jersey. The company has undergone a name change from Aptorum Group Ltd, effective March 9, 2018. The recent activity in stock transactions may suggest a strategic pivot or renewed focus on growth initiatives within the company, aligning with broader trends in the biotechnology sector.

Conclusion

While the filing provides substantial information regarding Alidad Mireskandari's recent stock transactions, it does not include details on the company's current financial performance or future strategic plans. Stakeholders may be keen to see how these stock options and acquisitions play into Niki BioSolutions' overall strategy moving forward.